RecruitingRecruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743 · Novartis
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2a/b Study Assessing the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
About this study
This study is a Phase 2a/b, randomized, double-blind, placebo-controlled, multi-center trial involving participants with SjD. The study consists of three parts (Part A, Part B, and Part C).
The study includes a screening period of up to 8 weeks to assess eligibility, a 52-week treatment period, and a 4-week safety follow-up period after the last dose of study treatment.
Eligibility criteria
Key Inclusion Criteria:
• Participants must have a diagnosis of SjD according to the ACR/EULAR 2016 classification criteria at screening:
\- Positive anti-Ro (SSA) antibodies at screening. Participants negative for anti-Ro/SSA antibodies are eligible if they have documented previous biopsy showing evidence of salivary gland inflammation consistent with SjD.
Key Exclusion Criteria:
* Presence of another autoimmune rheumatic disease that is active at screening and constitutes the principal illness.
* Exclusion based on medications being used for SjD:
* Participants taking \> 400 mg/day hydroxychloroquine are excluded. Participants taking ≤400 mg/day hydroxychloroquine should be on a stable dose for at least 4 weeks prior to randomization.
* Participants taking \> 400 mg/day hydroxychloroquine are excluded. Participants on ≤ 400 mg/day of hydroxychloroquine should be on a stable dose for at least 4 weeks prior to randomization.
* Prior treatment with any of the following within 3 months prior to randomization: belimumab, abatacept, anti-tumor necrosis factor alpha biologic agents, immunoglobulins, plasmapheresis, intravenous (i.v.) or oral cyclophosphamide, mycophenolate mofetil, i.v. or oral cyclosporine A, or any other immunosuppressants (e.g., JAK inhibitors or other kinase inhibitors, IL-2, anti-IL-6, anti-IL-17).
* Previous treatment with any cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to screening.
* Any viral, bacterial or other infections at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infection.
* History of malignancy of any organ system (other than localized non melanoma carcinoma of the skin or in situ cervical cancer) within the last five years of randomization or any malignancy not in remission.
Other protocol-defined inclusion/exclusion criteria may apply.
Study design
Enrollment target: 344 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-08-24
Estimated completion: 2029-03-19
Last updated: 2026-11-09
Interventions
Drug: DDY391Drug: Placebo
Primary outcomes
- • Part A and B: Change from baseline in ESSDAI score (Baseline, Week 24)
- • Part C: Change from baseline in ESSPRI (Baseline, Week 24)
Sponsor
Novartis Pharmaceuticals · industry
Contacts & investigators
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · 1-888-669-6682
ContactNovartis Pharmaceuticals · contact · +41613241111
All locations (31)
Arizona Arthritis and Rheumatology Associates PLLCRecruiting
Avondale, Arizona, United States
Clinical Res Of W FloridaRecruiting
Clearwater, Florida, United States
Clinical Research of West Florida IncRecruiting
Tampa, Florida, United States
Chicago Clinical Research InstRecruiting
Chicago, Illinois, United States
Willow Rheumatology WellnessRecruiting
Willowbrook, Illinois, United States
RAO Research LLCRecruiting
Oklahoma City, Oklahoma, United States
Altoona Center for Clin ResRecruiting
Duncansville, Pennsylvania, United States
Rheumatology Specialty Center - Willow Grove OfficeRecruiting
Willow Grove, Pennsylvania, United States
Shelby Research LLCRecruiting
Memphis, Tennessee, United States
Stryde Research-Allen ArthritisRecruiting
Allen, Texas, United States
Novel Research LLCRecruiting
Bellaire, Texas, United States
Arthritis Care of TexasRecruiting
Corpus Christi, Texas, United States
Novartis Investigative SiteRecruiting
Southport, Queensland, Australia
Novartis Investigative SiteRecruiting
Nedlands, Western Australia, Australia
Novartis Investigative SiteRecruiting
Rimouski, Quebec, Canada
Novartis Investigative SiteRecruiting
Sherbrooke, Quebec, Canada
Novartis Investigative SiteRecruiting
Trois-Rivières, Quebec, Canada
Novartis Investigative SiteRecruiting
Hefei, Anhui, China
Novartis Investigative SiteRecruiting
Nanjing, Jiangsu, China
Novartis Investigative SiteRecruiting
Taiyuan, Shanxi, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Bogota, Cundinamarca, Colombia
Novartis Investigative SiteRecruiting
Paris, France
Novartis Investigative SiteRecruiting
Kaposvár, Hungary
Novartis Investigative SiteRecruiting
Kfar Saba, Israel
Novartis Investigative SiteRecruiting
Petah Tikva, Israel
Novartis Investigative SiteRecruiting
Ramat Gan, Israel
Novartis Investigative SiteRecruiting
Tel Aviv, Israel
Novartis Investigative SiteRecruiting
Tsrifin, Israel
Novartis Investigative SiteRecruiting
Groningen, Provincie Groningen, Netherlands